I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| classical monocyte | 4 studies | 21% ± 3% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| classical monocyte | 4 studies | 21% ± 3% |
Insufficient scRNA-seq data for expression of TLR8 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 99% | 629.38 | 575 / 578 | 81% | 4.74 | 933 / 1155 |
| breast | 64% | 71.73 | 295 / 459 | 67% | 2.62 | 751 / 1118 |
| intestine | 76% | 106.06 | 730 / 966 | 51% | 1.78 | 268 / 527 |
| bladder | 71% | 74.76 | 15 / 21 | 45% | 1.83 | 226 / 504 |
| stomach | 44% | 53.01 | 158 / 359 | 61% | 2.77 | 175 / 286 |
| esophagus | 49% | 50.14 | 711 / 1445 | 51% | 1.39 | 94 / 183 |
| spleen | 99% | 2043.84 | 239 / 241 | 0% | 0 | 0 / 0 |
| kidney | 28% | 33.49 | 25 / 89 | 70% | 4.08 | 632 / 901 |
| lymph node | 0% | 0 | 0 / 0 | 97% | 23.33 | 28 / 29 |
| adipose | 92% | 254.30 | 1105 / 1204 | 0% | 0 | 0 / 0 |
| pancreas | 19% | 20.73 | 63 / 328 | 67% | 2.67 | 119 / 178 |
| peripheral blood | 83% | 7702.06 | 775 / 929 | 0% | 0 | 0 / 0 |
| adrenal gland | 69% | 74.90 | 178 / 258 | 13% | 0.25 | 31 / 230 |
| thymus | 37% | 32.35 | 243 / 653 | 43% | 1.05 | 263 / 605 |
| uterus | 35% | 29.42 | 60 / 170 | 39% | 1.28 | 181 / 459 |
| skin | 15% | 10.34 | 280 / 1809 | 58% | 3.26 | 274 / 472 |
| ovary | 19% | 17.40 | 34 / 180 | 48% | 1.37 | 206 / 430 |
| liver | 40% | 39.56 | 91 / 226 | 25% | 0.68 | 101 / 406 |
| prostate | 39% | 34.51 | 96 / 245 | 25% | 0.50 | 127 / 502 |
| tonsil | 0% | 0 | 0 / 0 | 64% | 3.41 | 29 / 45 |
| blood vessel | 64% | 102.70 | 857 / 1335 | 0% | 0 | 0 / 0 |
| brain | 16% | 14.68 | 428 / 2642 | 46% | 1.80 | 323 / 705 |
| heart | 45% | 43.03 | 391 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 9% | 0.21 | 7 / 80 |
| muscle | 8% | 4.75 | 66 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0002224 | Biological process | toll-like receptor signaling pathway |
| GO_0032728 | Biological process | positive regulation of interferon-beta production |
| GO_0006954 | Biological process | inflammatory response |
| GO_0071260 | Biological process | cellular response to mechanical stimulus |
| GO_0045087 | Biological process | innate immune response |
| GO_0007249 | Biological process | canonical NF-kappaB signal transduction |
| GO_0009615 | Biological process | response to virus |
| GO_0051607 | Biological process | defense response to virus |
| GO_0032695 | Biological process | negative regulation of interleukin-12 production |
| GO_0001932 | Biological process | regulation of protein phosphorylation |
| GO_0032727 | Biological process | positive regulation of interferon-alpha production |
| GO_0045089 | Biological process | positive regulation of innate immune response |
| GO_0032731 | Biological process | positive regulation of interleukin-1 beta production |
| GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
| GO_0016064 | Biological process | immunoglobulin mediated immune response |
| GO_0032757 | Biological process | positive regulation of interleukin-8 production |
| GO_0032729 | Biological process | positive regulation of type II interferon production |
| GO_0034158 | Biological process | toll-like receptor 8 signaling pathway |
| GO_0032755 | Biological process | positive regulation of interleukin-6 production |
| GO_0009897 | Cellular component | external side of plasma membrane |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0005789 | Cellular component | endoplasmic reticulum membrane |
| GO_0000139 | Cellular component | Golgi membrane |
| GO_0010008 | Cellular component | endosome membrane |
| GO_0036020 | Cellular component | endolysosome membrane |
| GO_0003677 | Molecular function | DNA binding |
| GO_0038023 | Molecular function | signaling receptor activity |
| GO_0038187 | Molecular function | pattern recognition receptor activity |
| GO_0003727 | Molecular function | single-stranded RNA binding |
| GO_0003723 | Molecular function | RNA binding |
| GO_0003725 | Molecular function | double-stranded RNA binding |
| Gene name | TLR8 |
| Protein name | Toll-like receptor 8 Toll-like receptor 8 transcript variant 4 Toll-like receptor 8 (CD antigen CD288) |
| Synonyms | UNQ249/PRO286 |
| Description | FUNCTION: Endosomal receptor that plays a key role in innate and adaptive immunity . Controls host immune response against pathogens through recognition of RNA degradation products specific to microorganisms that are initially processed by RNASET2 . Recognizes GU-rich single-stranded RNA (GU-rich RNA) derived from SARS-CoV-2, SARS-CoV-1 and HIV-1 viruses . Upon binding to agonists, undergoes dimerization that brings TIR domains from the two molecules into direct contact, leading to the recruitment of TIR-containing downstream adapter MYD88 through homotypic interaction . In turn, the Myddosome signaling complex is formed involving IRAK4, IRAK1, TRAF6, TRAF3 leading to activation of downstream transcription factors NF-kappa-B and IRF7 to induce pro-inflammatory cytokines and interferons, respectively . . |
| Accessions | ENST00000311912.5 [Q9NR97-2] A0AA49X8T4 Q9NR97 ENST00000218032.7 [Q9NR97-1] Q495P7 Q495P6 |
